Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT)

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages 1434-1444

  Woods, C P ^a   Corrigan, M ^a   Gathercole, L ^b   Taylor, A ^b   Hughes, B ^b   Gaoatswe, G ^a   Manolopoulos, K ^b   Hogan, A E ^a   O'Connell, J ^a   Stewart, P M ^c   Tomlinson, J W ^b   O'Shea, D ^a   Sherlock, M ^a,b,d  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CORTISONE; GLUCOCORTICOID; HYDROCORTISONE; LIVER ENZYME; GLUCOCORTICOID RECEPTOR;

ADIPOSE TISSUE; ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; MALE; METABOLITE; MICRODIALYSIS; OBESITY; OMENTUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE; TISSUE SPECIFICITY; TREATMENT RESPONSE; URINE LEVEL; WEIGHT REDUCTION; AGED; ANTIBODY SPECIFICITY; CASE CONTROL STUDY; CHEMISTRY; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; OBESITY, MORBID; PHYSIOLOGY; SUBCUTANEOUS FAT; URINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADULT; AGED; BARIATRIC SURGERY; CASE-CONTROL STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MICRODIALYSIS; MIDDLE AGED; OBESITY, MORBID; ORGAN SPECIFICITY; RECEPTORS, GLUCOCORTICOID; SUBCUTANEOUS FAT; WEIGHT LOSS;

EID: 84927654002     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4120     Document Type: Article

References (51)

1. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health. 2007;121(7):492-496.
2. Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S1-S8.
3. Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42(6):563-570.
4. Adams KF, Schatzkin A, Harris TB, et al. Estimates for the year 2000 and projections for 2030. N Engl J Med. 2006;355:763-778.
5. Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233-244.
6. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a casecontrol study. Lancet. 366:1640-1649.
7. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138:24-32.
8. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. NEngl J Med. 2010;363(23):2211-2219.
9. Veilleux A, Laberge PY, Morency J, Noël S, Luu-The V, Tchernof A. Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue. J Steroid Biochem Mol Biol. 2010;122(1-3):28-34.
10. Travison TG, O'Donnell AB, Araujo et al. Cortisol levels and measures of body composition in middle-aged and older men. Clin Endocrinology (Oxf). 2007;67(1):71-77.
11. Gathercole LL, Lavery GG, Morgan SA, et al. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev. 2013;34:525-555.
12. Chapman K, Holmes M, Seckl J. 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev. 2013;93(3):1139-1206.
13. Rask E. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab. 2001;86(3):1418-1421.
14. Lindsay RS. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab. 2003;88:2738-2744.
15. Engeli S, Böhnke J, Feldpausch M, et al. Regulation of 11β-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res. 2004;12(1):9-17.
16. Kannisto K, Pietiläinen KH, Ehrenborg E, et al. Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab. 2004;89(9):4414-4421.
17. Rask E, Walker BR, Söderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab. 2002;87(7):3330-3336.
18. Tomlinson JW. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab. 2002;87(12):5630-5635.
19. Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L, Stewart PM. Weight loss increases 11β-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J Clin Endocrinol Metab. 2004;89(6):2711-2716.
20. Purnell JQ, Kahn SE, Samuels MH, Brandon D, Loriaux DL, Brunzell JD. Enhanced cortisol production rates, free cortisol, and 11β-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. AmJ Physiol Endocrinol Metab. 2009;296(2):E351-E357.
21. Simonyte K, Olsson T, Näslund I, et al. Weight loss after gastric bypass surgery in women is followed by a metabolically favorable decrease in 11β-hydroxysteroid dehydrogenase 1 expression in subcutaneous adipose tissue. J Clin Endocrinol Metab. 2010;95(7):3527-3531.
22. Johnstone AM, Faber P, Andrew R, et al. Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese men. Eur J Endocrinol. 2004;150(2):185-194.
23. Desbriere R, Vuaroqueaux V, Achard V, et al. 11β-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14(5):794-798.
24. Baudrand R, Carvajal CA, Riquelme A, et al. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obes Surg. 2010;20(1):77-83.
25. Veilleux A, Rhéaume C, Daris M, Luu-The V, Tchernof A. Omental adipose tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab. 2009;94(9):3550-3557.
26. Torrecilla E, Fernández-Vázquez G, Vicent D, et al. Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes Surg. 2012;22(3):478-486.
27. Rask E, Simonyte K, Lönn L, Axelson M. Cortisol metabolism after weight loss: associations with 11 β-HSD type 1 and markers of obesity in women. Clin Endocrinol (Oxf). 2013;78(5):700-705.
28. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisonečortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84(3):1022-1027.
29. Tomlinson JW, Finney J, Hughes BA, Hughes SV, Stewart PM. Reduced glucocorticoid production rate, decreased 5'-reductase activity, and adipose tissue insulin sensitization after weight loss. Diabetes. 2008;57(6):1536-1543.
30. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet. 1997;349(9060):1210-1213.
31. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94(8):2692-2701.
32. Bujalska IJ, Gathercole LL, Tomlinson JW, et al. A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol. 2008;197(2):297-307.
33. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care. 2010;33(7):1516-1522.
34. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab. 2011;13(6):498-504.
35. Shah S, Hermanowski-Vosatka A, Gibson K, et al. Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J AmSoc Hypertens. 5(3):166-176.
36. Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK. Specificity of screening tests for Cushing's syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94(10):3857-3864.
37. Tomlinson JW, Sherlock M, Hughes B, et al. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab. 2007;92(3):857-864.
38. Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf). 1996;45(5):605-611.
39. Shackleton CH. Profiling steroid hormones and urinary steroids. J Chromatogr. 1986;379:91-156.
40. Shackleton CH, Macros PGM. Steroid profiling: diagnosis of disorders affecting steroid synthesis and metabolism. In: Encyclopedia of Mass Spectrometry. Amsterdam: Elsevier; 2006:789-813.
41. Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CH. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol. 2010;121(3-5):496-504.
42. Spurgeon SL, Jones RC, Ramakrishnan R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One. 2008;3(2):e1662.
43. Connell JO. Adipocyte size and function in severe obesity-a study of patients undergoing bariatric surgery, PhD thesis: 2011.
44. O'Connell J, Lynch L, Cawood TJ, et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One. 2010;5(4):e9997.
45. Valsamakis G, Anwar A, Tomlinson JW, et al. 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89(9):4755-4761.
46. Morton NM, Holmes MC, Fiévet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem. 2001;276(44):41293-41300.
47. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294(5549):2166-2170.
48. Leyvraz C, Verdumo C, Suter M, et al. Changes in gene expression profile in human subcutaneous adipose tissue during significant weight loss. Obes Facts. 2012;5(3):440-451.
49. Michalaki M, Kyriazopoulou V, Antonacopoulou A, et al. The expression of omental 11β-HSD1 is not increased in severely obese women with metabolic syndrome. Obes Facts. 2012;5(1):104-111.
50. Paulsen SK, Pedersen SB, Fisker S, Richelsen B. 11β-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring). 2007;15(8):1954-1960.
51. Goedecke JH, Wake DJ, Levitt NS, et al. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol (Oxf). 2006;65(1):81-87.